Inpharma

New targets for anxiolytics
pp. 2-2(1)

Management guidelines for onychomycosis have been prepared for dermatologists on behalf of the British Association of Dermatologists.
pp. 3-3(1)

ASCO's new conflict of interest policy
pp. 3-3(1)

Legislative proposals for the creation of a European Centre for Disease Prevention and Control
pp. 3-3(1)

The Association of the British Pharmaceutical Industry (ABPI) has launched a drug trials website
pp. 3-3(1)

China is accelerating the availability of products for the prevention, diagnosis and treatment of SARS
pp. 3-3(1)

New cancer and treatment-related anaemia practice guidelines have been released by the National Comprehensive Cancer Network (NCCN).
pp. 3-3(1)

The endpoints used by the US FDA to approve new oncology drug applications have been summarised
pp. 4-4(1)

Targeting huntingtin in Huntington's disease
pp. 4-4(1)

Alosetron worth the risk in irritable bowel syndrome?
pp. 4-4(1)

Infants enrolled in US Medicaid have a 2-3 times higher rate of hospitalisation due to respiratory syncytial virus (RSV) infections
pp. 4-4(1)

Savings of nearly $US1.5 million have been realised by CHA Health in the first 2 years of a cancer disease management (DM) programme
pp. 5-5(1)

Adjunctive topiramate economically attractive in refractory epilepsy
pp. 5-5(1)

Standard-dose PPIs worth it for GERD in Hong Kong
pp. 5-5(1)

Healthcare costs are nearly 50% higher than necessary for some health illiterate patients in the US
pp. 5-5(1)

Oral deferasirox may be an effective iron chelator in patients with thalassaemia and transfusional iron overload
pp. 6-6(1)

Immune tolerance to long-term laronidase in MPS-I
pp. 6-6(1)

Pirfenidone may be more effective than prednisone in the treatment of idiopathic pulmonary fibrosis
pp. 6-6(1)

A combination of TA-CIN and TA-HPV candidate vaccines demonstrated clear responses
pp. 6-6(1)

Ximelagatran reduces stroke risk in atrial fibrillation
pp. 7-8(2)

Protein S neuroprotective in murine ischaemic stroke model
pp. 8-8(1)

Oculex Pharmaceuticals has announced positive clinical results for its ocular implant `Posurdex'
pp. 8-8(1)

siRNAs protect against fulminant hepatitis
pp. 9-9(1)

S 18886 improves endothelial function in CAD
pp. 9-9(1)

Treatment with sarpogrelate helps to prevent restenosis after coronary stenting
pp. 9-9(1)

Genentech and XOMA have decided to discontinue testing efalizumab [`Raptiva'] in rheumatoid arthritis
pp. 9-9(1)

Sustained response to lamivudine in chronic hepatitis B
pp. 10-10(1)

Sildenafil improves pulmonary haemodynamics and exercise capacity in patients with severe pulmonary hypertension
pp. 10-10(1)

Insulin gene transfer enhances human islet graft function
pp. 10-10(1)

Two phase III trials investigating the ability of tariquidar to enhance the efficacy of chemotherapy agents in non-small-cell lung cancer will be discontinued
pp. 10-10(1)

Galantamine: dual mechanism advantageous in dementia
pp. 11-12(2)

Epoprostenol improves Eisenmenger physiology
pp. 12-12(1)

High-dose chemotherapy + stem cells for multiple myeloma
pp. 13-13(1)

SSRIs vs TCAs: comparable efficacy in primary care
pp. 13-13(1)

Zolmitriptan useful in migrainous vertigo?
pp. 13-13(1)

Lamotrigine, lithium both effective long-term in bipolar disorder
pp. 13-13(1)

Anticoagulants appear to be safe and may be beneficial in the treatment of cerebral sinus thrombosis
pp. 14-14(1)

Standard treatment protocol for SARS
pp. 14-14(1)

Milnacipran may be effective for the treatment of bulimia nervosa
pp. 14-14(1)

The serotonin2A antagonist mianserin improves neurocognitive functioning in patients with chronic schizophrenia
pp. 14-14(1)

High dose interferon--1b effective in both early and advanced MS
pp. 15-16(2)

Deflazacort preserves cardiac function in DMD
pp. 17-17(1)

Topical cream containing glucosamine plus chondroitin sulfate and camphor relieves the pain associated with osteoarthritis of the knee
pp. 17-17(1)

Donepezil may be of benefit in chronic aphasia
pp. 17-17(1)

Does etidronic acid have potential in rheumatoid arthritis?
pp. 18-18(1)

Perindopril: superior induction of coronary fibrinolytic activity
pp. 18-18(1)

Insulin benefit in critical care thanks to reduced CRP
pp. 19-19(1)

Baclofen may be useful in GERD
pp. 19-19(1)

Clarithromycin crosses the placenta more effectively than other macrolides
pp. 19-19(1)

Acceptance of adverse event risk is low in RA
pp. 20-20(1)

Concomitant metronidazole increases busulfan toxicity
pp. 20-20(1)

SSRIs do not appear to be associated with an increased rate of suicide
pp. 20-20(1)

Short-term cilostazol has beneficial effects in AV block
pp. 20-20(1)

Co-proxamol dangerous in overdose: should access be restricted?
pp. 21-21(1)

Risk of EPS no lower with new generation antipsychotics?
pp. 21-21(1)

Glycoprotein (GP) IIb/IIIa antagonists appear to be associated with a modest increase in bleeding risk
pp. 21-21(1)

Long-term menotropin use may increase breast cancer risk
pp. 21-21(1)

Recent product approvals in Canada
pp. 22-22(1)

US market news
pp. 22-22(1)

EU market news
pp. 22-22(1)

Gefitinib [`Iressa'; AstraZeneca] has been approved by the Australian Therapeutic Goods Administration
pp. 22-22(1)

The Chinese State Drug Administration has approved Dragon Pharmaceutical's epoetin alfa
pp. 22-22(1)

Product Introductions
pp. 23-23(1)